170 related articles for article (PubMed ID: 4060364)
21. Urinary modified nucleosides as novel biomarkers for diagnosis and prognostic monitoring of urothelial bladder cancer.
Zhang YR; Shi L; Wu H; Tang DD; Wang SM; Liu HM; Zhang LR; Song DK
Tumori; 2014; 100(6):660-6. PubMed ID: 25688500
[TBL] [Abstract][Full Text] [Related]
22. Significance of urinary neopterin in patients with malignant tumors of the genitourinary tract.
Aulitzky W; Frick J; Fuchs D; Hausen A; Reibnegger G; Wachter H
Cancer; 1985 Mar; 55(5):1052-5. PubMed ID: 3967190
[TBL] [Abstract][Full Text] [Related]
23. A novel enzymatic pathway leading to 1-methylinosine modification in Haloferax volcanii tRNA.
Grosjean H; Constantinesco F; Foiret D; Benachenhou N
Nucleic Acids Res; 1995 Nov; 23(21):4312-9. PubMed ID: 7501451
[TBL] [Abstract][Full Text] [Related]
24. An immunohistochemical analysis for cancer of the esophagus using monoclonal antibodies specific for modified nucleosides.
Masuda M; Nishihira T; Itoh K; Mizugaki M; Ishida N; Mori S
Cancer; 1993 Dec; 72(12):3571-8. PubMed ID: 8252470
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of urinary nucleosides in breast cancer patients before and after tumor removal.
Cho SH; Choi MH; Lee WY; Chung BC
Clin Biochem; 2009 Apr; 42(6):540-3. PubMed ID: 19186175
[TBL] [Abstract][Full Text] [Related]
26. Excretion patterns of pseudouridine and beta-aminoisobutyric acid in patients with tumours of the upper urinary tract.
Kvist E; Sjølin KE; Iversen J
Scand J Urol Nephrol; 1990; 24(4):287-92. PubMed ID: 2274753
[TBL] [Abstract][Full Text] [Related]
27. Relationship of urinary pseudouridine and 1-methyladenosine to activity of leukemia and lymphoma.
Itoh K; Konno T; Sasaki T; Ishiwata S; Ishida N; Misugaki M
Clin Chim Acta; 1992 Mar; 206(3):181-9. PubMed ID: 1606704
[TBL] [Abstract][Full Text] [Related]
28. Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients.
Frickenschmidt A; Frohlich H; Bullinger D; Zell A; Laufer S; Gleiter CH; Liebich H; Kammerer B
Biomarkers; 2008 Jun; 13(4):435-49. PubMed ID: 18484357
[TBL] [Abstract][Full Text] [Related]
29. Monitoring of urinary excretion of modified nucleosides in cancer patients using a set of six monoclonal antibodies.
Reynaud C; Bruno C; Boullanger P; Grange J; Barbesti S; Niveleau A
Cancer Lett; 1992 Jan; 61(3):255-62. PubMed ID: 1739950
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer prognostic significance of some modified urinary nucleosides.
Sasco AJ; Rey F; Reynaud C; Bobin JY; Clavel M; Niveleau A
Cancer Lett; 1996 Nov; 108(2):157-62. PubMed ID: 8973589
[TBL] [Abstract][Full Text] [Related]
31. Reduced levels of modified nucleosides in the urine of autistic children. Preliminary studies.
Bobrowska-Korczak B; Gątarek P; Rosiak A; Giebułtowicz J; Kałużna-Czaplińska J
Anal Biochem; 2019 Apr; 571():62-67. PubMed ID: 30771338
[TBL] [Abstract][Full Text] [Related]
32. Study of nucleic acid metabolism in two astronauts.
Szabo LD; Keresztes P; Pallos JP; Csato E; Predmerszky T
Adv Space Res; 1984; 4(10):15-8. PubMed ID: 11539621
[TBL] [Abstract][Full Text] [Related]
33. Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring.
Feng B; Zheng MH; Zheng YF; Lu AG; Li JW; Wang ML; Ma JJ; Xu GW; Liu BY; Zhu ZG
J Gastroenterol Hepatol; 2005 Dec; 20(12):1913-9. PubMed ID: 16336453
[TBL] [Abstract][Full Text] [Related]
34. Urinary nucleosides as biological markers for patients with colorectal cancer.
Zheng YF; Yang J; Zhao XJ; Feng B; Kong HW; Chen YJ; Lv S; Zheng MH; Xu GW
World J Gastroenterol; 2005 Jul; 11(25):3871-6. PubMed ID: 15991285
[TBL] [Abstract][Full Text] [Related]
35. Isolation and identification of urinary nucleosides. Applications of high-performance liquid chromatographic methods to the synthesis of 5'-deoxyxanthosine and the simultaneous determination of 5,6-dihydrouridine and pseudouridine.
Nakano K; Yasaka T; Schram KH; Reimer ML; McClure TD; Nakao T; Yamamoto H
J Chromatogr; 1990 Aug; 515():537-46. PubMed ID: 2283377
[TBL] [Abstract][Full Text] [Related]
36. Urinary excretion of six modified nucleosides by patients with breast carcinoma.
Vreken P; Tavenier P
Ann Clin Biochem; 1987 Nov; 24 ( Pt 6)():598-603. PubMed ID: 3426126
[TBL] [Abstract][Full Text] [Related]
37. Urinary excretion of modified nucleosides as biological marker of RNA turnover in patients with cancer and AIDS.
Nakano K; Nakao T; Schram KH; Hammargren WM; McClure TD; Katz M; Petersen E
Clin Chim Acta; 1993 Sep; 218(2):169-83. PubMed ID: 7508341
[TBL] [Abstract][Full Text] [Related]
38. Urinary excretion patterns of modified nucleosides, pseudouridine and 1-methyladenosine, in healthy individuals.
Itoh K; Aida S; Ishiwata S; Sasaki S; Ishida N; Mizugaki M
Clin Chim Acta; 1993 Aug; 217(2):221-3. PubMed ID: 8261632
[No Abstract] [Full Text] [Related]
39. Diagnostic use of anti-modified nucleoside monoclonal antibody.
Itoh K; Ishiwata S; Ishida N; Mizugaki M
Tohoku J Exp Med; 1992 Oct; 168(2):329-31. PubMed ID: 1306318
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of carcinoembryonic antigen, tissue polypeptide antigen, placental alkaline phosphatase, and modified nucleosides as biological markers in malignant lymphomas.
Rasmuson T; Björk GR; Damber L; Holm SE; Jacobsson L; Jeppsson A; Littbrand B; Stigbrand T; Westman G
Recent Results Cancer Res; 1983; 84():331-43. PubMed ID: 6342073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
